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AbstrAct 
The Brazilian Sleep Association brought together specialists in sleep medicine, in order 
to develop new guidelines on the diagnosis and treatment of insomnias. The following 
subjects were discussed: concepts, clinical and psychosocial evaluations, recommendations 
for polysomnography, pharmacological treatment, behavioral and cognitive therapy, 
comorbidities and insomnia in children. Four levels of evidence were envisaged: standard, 
recommended, optional and not recommended. For diagnosing of insomnia, psychosocial 
and polysomnographic investigation were recommended. For non-pharmacological 
treatment, cognitive behavioral treatment was considered to be standard, while for 
pharmacological treatment, zolpidem was indicated as the standard drug because of its 
hypnotic profile, while zopiclone, trazodone and doxepin were recommended. 
Key words: insomnia, diagnosis of insomnia, treatment of insomnia, cognitive behavioral 
therapy.
Novas diretrizes no diagnóstico e tratamento das insônias
resumo
A Associação Brasileira de Sono reuniu especialistas em medicina do sono com o 
objetivo de desenvolver novas diretrizes no diagnóstico e tratamento das insônias. 
Nós consideramos quatro níveis de evidência: padrão, recomendado, opcional e não 
recomendado. Os tópicos abordados foram: conceito, avaliação clínica e psicossocial, 
indicação da polissonografia, tratamento farmacológico, terapia comportamental cognitiva, 
comorbidades e insônia na infância. Para o diagnóstico da insônia, foi recomendada uma 
avaliação psicossocial e a realização da polissonografia, enquanto que no que se refere 
ao tratamento, foi estabelecido como padrão a indicação da terapia comportamental 
cognitiva, e, quanto ao tratamento farmacológico, foi indicado o uso do zolpidem como 
hipnótico padrão, e sendo recomendado o zopiclone, a trazodona e a doxepina.
Palavras-chave: insônia, diagnóstico da insônia, tratamento da insônia, terapia compor-
tamental cognitiva.
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Even today, insomnia remains a clinical 
entity that is difficult to diagnose and com-
plex to treat, demanding an approach with 
appropriate strategy and planning. Insom-
nia, as a symptom, syndrome or disease, 
has serious social and professional conse-
quences, affecting daily activities and ren-
dering individuals incapable of performing 
their tasks. It therefore generates a high 
cost for society.
In November 2008, the Brazilian Sleep 
Society brought together doctors who 
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specialize in sleep medicine, in São Paulo. The meet-
ing aimed to provide new guidelines for diagnosing and 
treating insomnia. During this meeting, the following 
subjects were considered: concepts, clinical and psycho-
social evaluations, recommendations for polysomnog-
raphy, pharmacological treatment, behavioral and cog-
nitive therapy, comorbidities and insomnia in children.
METHOD
Based on searches in the literature for articles, reviews 
and meta-analyses, five levels of evidence were put for-
ward as recommendations for managing insomnia:
Level I - Randomized trials with low false-positive (al-
pha) and low false-negative (beta) errors (high power); ev-
idence obtained from meta-analyses on randomized con-
trolled trials; Level II - Randomized trials with high false-
positive (alpha) and (or) high false-negative (beta) errors 
(low power); evidence obtained from at least one ran-
domized controlled trial; Level III - Nonrandomized con-
current cohort comparisons between patients with and 
without receiving a concomitant nutritional intervention; 
evidence obtained from at least one well-designed, con-
trolled study, without randomization; Level IV - Nonran-
domized historical cohort comparisons between current 
patients who received a nutritional intervention, and for-
mer patients (from the same institution or from the lit-
erature) who did not; Level V - Case series without con-
trols; evidence obtained from expert committee reports 
or opinions and/or clinical experiences from respected 
authorities. Based on these five levels of evidence, the rec-
ommendations for interventions were considered to be: 
standard (levels I and II); recommended (levels III and 
IV), optional (level V) and not recommended, when no 
level of evidence existed1,2.
 
Concept (standard)
Insomnia is defined as a disorder that is character-
ized by difficulty in falling asleep or maintaining sleep. 
Furthermore, insomnia is also related to dissatisfaction 
with the quality of sleep, thus resulting in daily physical 
and emotional symptoms that have an impact on social 
and cognitive performance3.
Classification (standard)
According to the latest classification of sleep disorders 
(2005), insomnia is divided into the following forms: acute 
insomnia, psychophysiological insomnia, paradoxical in-
somnia, idiopathic insomnia, insomnia associated with 
mental disorders, insomnia associated with systemic dis-
eases and insomnia associated with inadequate habits4-6.
Acute insomnia, transitory insomnia  
or adjustment insomnia
The essential element for this diagnosis is the pres-
ence of symptoms of acute insomnia caused by a trigger-
ing causal factor that is clearly identified in an individu-
al who previously had a normal sleeping pattern, without 
insomnia complaints. This clinical condition lasts no lon-
ger than one month4.
Primary chronic insomnia
In the etiopathogenesis of primary insomnia, three 
points should be considered: predisposing (genetic and 
constitutional), precipitating and perpetuating factors. 
Predisposing factors depend on hyperactivity of the 
awakening system (stress response mechanisms), hy-
peractivity of the hypothalamic-pituitary-adrenal axis, 
anxiety and depression, abnormalities in the mecha-
nisms of sleep-wakefulness homeostasis, abnormali-
ties in the circadian rhythm (circadian sleep-wakeful-
ness control) and abnormalities of the intrinsic mech-
anisms of sleep-wakefulness control7-11. The precipitat-
ing and perpetuating factors depend on psychosocial fac-
tors, behavioral changes and cognitive characteristics. 
Primary insomnia can be divided in three subtypes, 
namely psychophysiological, idiopathic and paradoxi-
cal4. Psychophysiological insomnia occurs concomitant-
ly with a cognitive hyperalert state that is characterized 
by anxiety related to the act of sleeping and the presence 
of neurocognitive symptoms such as fatigue and irrita-
bility. Idiopathic insomnia starts before puberty and per-
sists throughout adulthood, and a family history of in-
somnia is often present. In paradoxical insomnia, sub-
jective complaints of poor quality sleep can be observed, 
despite the lack of objective sleep abnormalities on poly-
somnography. This subtype of insomnia is related to sleep 
misperception.
Associated insomnia
[1] Mental disorder - The essential factor of this type 
of insomnia is the temporal and causal relationship with 
an underlying mental disorder. Mood disorders such as 
depression, dysthymia, cyclothymia, bipolar disorder, 
anxiety, schizophrenia and somatoform disorders are ex-
amples of mental disorders associated with this type of 
insomnia3-5,12-18. 
[2] Inadequate sleep hygiene - This is related to hab-
its that are inappropriate for good quality of sleep, for ex-
ample psychologically stressful activities, consumption 
of caffeine, nicotine, alcohol and heavy meals, vigorous 
physical activity close to bed time, inconstant time for 
going to sleeping and waking up, long naps or naps near 
the main time for sleeping4. 
[3] Medical condition - This sleep disorder is related 
to particular medical conditions, for example painful syn-
dromes, infections, metabolic diseases, hyperthyroidism 
and neurological diseases4. 
[4] Use of substances or medication - This sleep disor-
der is related to the use of a drug or substance such as al-
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cohol, stimulants (amphetamine and derivatives) or an-
tidepressives4.
Comorbidities
Obstructive sleep apnea
In 1973, Guilleminault et al described the association 
between insomnia and obstructive sleep apnea, and called 
it “sleep-insomnia apnea syndrome”19. The relationship 
between these two common sleep disorders is complex 
and unclear. There is a higher incidence of breathing dis-
orders in insomniac patients than there is in the gener-
al population20,21. The severity of insomnia symptoms is 
strongly correlated with the severity of apnea, thereby 
characterizing comorbidity. Lichstein et al demonstrat-
ed that high proportions of individuals, particularly the 
elderly, present this combined condition of undiagnosed 
sleep apnea and insomnia22. Therefore, polysomnography 
(PSG) can help identify a substantial number of breathing 
disorders that are associated with insomnia23,24.
Women at the premenopausal and menopausal peri-
ods are more likely to develop sleep complaints and disor-
ders than are women of a fertile age. Conjugated hormon-
al therapy (estrogen and progesterone) has been shown 
to efficiently improve general sleep complaints, as well as 
insomnia and OSAS25. Benzodiazepine drugs are asso-
ciated with reductions in wakefulness, reductions in the 
muscle tonus of airways and decreases in the ventilatory 
response to hypoxemia. Therefore, these drugs are con-
sidered to be inappropriate for treating these comorbidi-
ties. The use of CPAP or oral devices also interferes neg-
atively in the quality of sleep, particularly during the ad-
aptation phases.
Fibromyalgia
Patients with fibromyalgia present persistent tired-
ness and physical fatigue, associated with non-restoring 
sleep and diffuse muscle pain. Usually, these patients have 
the perception of a sleep disorder associated with fatigue. 
Pharmacological treatment mainly consists of tricycles 
antidepressants and cyclobenzaprine26-32.
Circadian rhythm disorders
The delayed sleep phase syndrome is a circadian 
rhythm disorder, characterized by delays in falling asleep 
and in waking in the morning. This condition usual-
ly starts during childhood and adolescence, and is sel-
dom misinterpreted as insomnia, particularly idiopath-
ic insomnia33-42.
Restless legs syndrome and 
periodic movements of limbs
The restless legs syndrome is characterized by senso-
ry disorders that mainly affect the lower limbs, particu-
larly before falling sleep, thus leading to difficulty in fall-
ing asleep. Periodic movements of limbs usually accom-
pany the restless legs syndrome during sleep, leading to 
a fragmented sleeping pattern, which affects the quality 
of sleep. Periodic movements of the lower limbs can oc-
cur during sleep, independently of the existence of rest-
less legs syndrome. In these cases, the repercussions on 
the sleep profile, with insomnia or daytime hypersomno-
lence, must be analyzed one by one, in each case43.
Evaluation
When considering the etiopathogenesis of insomnia, 
it is important to highlight that insomnia may be of bi-
ological, environmental, behavioral or psychological na-
ture. Likewise, the factors causing and perpetuating in-
somnia are interrelated with social, professional and fam-
ily factors. Therefore, insomnia evaluations need to be 
broad-based, covering the patients’ medical, psychologi-
cal and social characteristics.
Medical evaluation (standard)
Evaluations on insomniac patients should begin by 
taking a rigorous and detailed medical history in which 
the history of symptoms is recorded, including the start 
of insomnia and its progression to a chronic condition, 
along with treatments already used and repercussions 
of the abnormal sleeping pattern during the day, such as 
somnolence, tiredness, fatigue and reduction of attention, 
concentration and memory44.
Nighttime habits that should be recorded include: bed-
time, activities in bed, turning off lights, time to fall asleep, 
time to waking up in the morning, time to getting up, sleep 
quality, number of awakenings, time spent awake dur-
ing the night and reports of snoring and leg movements.
Day habits that should be recorded include: meal-
times, work and study periods, daytime naps, physical 
activity, smoking habit, alcohol intake, use of drugs and 
medications.
Bedroom conditions that should be recorded include: 
condition of the bed, mattress and pillows, number of 
people who sleep in the same bed, luminosity, noise, tem-
perature and presence of a TV, computer or audio equip-
ment in the bedroom.
Psychosocial evaluation (recommended)
This has the aim of investigating, in greater detail, the 
main precipitating and perpetuating factors of insomnia. 
A psychosocial evaluation must be carried out, taking 
into account the systemic focus, i.e. the insomnia symp-
toms are analyzed within the context of patients lives, and 
what these symptoms allow or cover45-48.
Subsidiary examinations (recommended)
It is recommended that every insomniac patient 
should undergo complementary examinations when there 
is a suspicion of any systemic disease.
Questionnaires (recommended)
The use of a sleep diary, as well as other question-
naires, is fundamental to cognitive-behavioral therapy.
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Polysomnography (recommended)
In order to investigate comorbidities such as obstruc-
tive sleep apnea, and for objective evaluation of sleep in 
cases of diagnosing inadequate perception, polysomnog-
raphy is recommended as an auxiliary method for diag-
nosing of insomnia, whenever possible49-52.
Treatment of primary insomnia
Cognitive-behavioral therapy (standard)
Today, cognitive-behavioral therapy (CBT) is a stan-
dard treatment for primary insomnia. It must not be 
used alone but, rather, in association with pharmaco-
logical therapy53-58. CBT presents an advantage over 
pharmacological treatment: the low risk of side ef-
fects and the long-term maintenance of sleep pattern 
improvement. CBT has a limited and defined peri-
od of use, from four to eight sessions. It is a focal and 
direct type of therapy, in which patients play an ac-
tive role and are co-responsible for their treatment. 
It can be undertaken individually or in groups59-62.
The interventions are educational, behavioral and cog-
nitive, and their theoretical basis is the behavioral mod-
el of insomnia proposed by Spielman. According to this 
model, three main factors can cause insomnia: predis-
posing, precipitating and perpetuating factors. The main 
CBT targets are the precipitating and perpetuating fac-
tors. The main behavioral and cognitive techniques are 
sleep hygiene, stimulus-control therapy, therapy of bed-
time and sleeping time restriction, relaxation techniques, 
cognitive restructuring, paradoxical intention and cogni-
tive therapy in sleep misperception disorders63-67.
[1] Sleep hygiene: This is a psychoeducational inter-
vention containing basic information on sleep habits and 
hygiene. It includes instructions for establishing regular 
sleeping times; going to bed only when feeling sleepy 
and not using the bed as a means of trying to sleep; not 
spending the day worrying about sleeping time; having 
control over time; avoiding the use of stimulants (cof-
fee, cigarettes, drugs, black tea, Coca-Cola and choco-
late); avoiding alcohol consumption before sleeping; and 
avoiding high liquid consumption before sleeping. It in-
cludes suggestions for dinner (light foods) not less than 
two hours before going to sleep, and for regular physi-
cal activity, preferably in the mornings. It evaluates the 
bedroom conditions: comfort, temperature, noise, and 
stresses the importance of having a bedroom that is si-
lent, aired, clean and organized.
[2] Stimulus-control therapy: This aims towards edu-
cating insomniac patients on how to establish a more ap-
propriate sleep-wakefulness rhythm and limit the time 
awake and the behavior allowed in the bedroom/bed. The 
main instructions for patients include the following items: 
to go to bed only when feeling sleepy; avoid any behav-
ior other than sleep or sex in the bedroom/bed; if feeling 
incapable of sleeping, the patient should get up from bed 
and go to another place to do some relaxing activity in 
an environment with little light, and only go back to bed 
when feeling somnolence again; to keep to a fixed time 
for waking up, seven days per week, independently of the 
amount of sleep obtained; not to nap or to lie down dur-
ing the day, to remove the TV, stereo and computer from 
the bedroom; not to eat, read, work, watch TV or use a 
computer in the bedroom/bed. 
[3] Therapy of bedtime and sleeping time restriction: 
The aim of this therapy is to consolidate sleep through 
restricting the time that patients spend in bed to the av-
erage time they spend sleeping (i.e. the number of hours 
that they really spend sleeping), based on the information 
in the sleep diary. This technique creates a mild state of 
sleep deprivation that may cause daytime somnolence. 
However, at the same time, it provides sleep consolida-
tion, thus making it easier to fall asleep, improving sleep 
efficiency and decreasing latency and variability between 
nights. It is not recommended to have less than four to 
five hours of sleep, and the necessary adjustments must 
be made in relation to time spent in bed, according to pa-
tients’ responses to the proposed treatment. If patients 
reach 90% sleep efficiency, 15 minutes are added to the 
time allowed in bed and, if the efficiency is less than 85%, 
15 minutes are taken away.
[4] Relaxation techniques: The aim of teaching relax-
ation techniques is to show patients how tense and hy-
pervigilant they are during both day and night. Progres-
sive relaxation is the treatment for insomnia that has been 
studied most. Patients are guided to tension and relax 
the major muscle groups sequentially, while observing the 
sensation of tension and relaxation. 
[5] Cognitive restructuring: This is mainly based on 
cognitive symptoms that can cause or perpetuate insom-
nia. Cognitive restructuring works on concerns, thoughts, 
false attitudes, irrational beliefs about sleep and amplifi-
cation of its consequences, false ideas about the causes 
of insomnia and disbelief about sleep induction practic-
es and about their own capacity to sleep. The idea is to 
make patients abandon the symptoms of insomnia, by re-
minding them that the way in which events are thought 
about or judged determines the way that individuals feel 
about them. 
[6] Paradoxical intention: This technique reduces the 
anticipatory anxiety associated with the fear of trying 
to fall sleep and not being capable of doing so, since in-
somniacs usually believe that they have lost their natu-
ral capacity to fall asleep. Patients are instructed to go to 
bed and stay awake and try not to sleep; this makes them 
more relaxed and not under obligation to fall asleep. They 
consequently fall asleep faster.
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[7] Cognitive therapy for sleep misperception disorders: 
This therapy works on the relationship between patients’ 
subjective perceptions of total sleeping time and the to-
tal sleeping time obtained through PSG. The intention of 
this approach is to give patients objective data on sleep 
efficiency obtained through PSG and make them com-
prehend that they are sleeping for longer than they think. 
This technique also makes them more relaxed regarding 
the quantity of sleep they consider necessary, and it en-
ables them to fall asleep more easily when this new real-
ity is acquired51-52.
Pharmacological treatment
Pharmacological treatment consists of the use of hyp-
notic drugs that induce sleep, mainly because they act on 
the main inhibitory system of the central nervous system, 
the GABA system. Additionally, substances presenting 
sedative effects, such as antidepressants, may be used. 
More recently, medications that act on melatoninergic 
receptors have been considered promising as drugs for 
treating insomnia68-72.
GABA-A receptor-selective agonist hypnotics
[1] Zolpidem (standard): This is the hypnotic drug 
used for treating insomnia. Zolpidem is an imidazopyri-
dine that was developed in 1980 and has been used since 
1990. It was the first selective α1 agonist. It is rapidly ab-
sorbed (in approximately one hour) and presents a short 
half-life of 2.5 hours. Its bioavailability ranges from 65% 
to 70%. Plasma concentration peaks occur 1.5 hours after 
drug intake. The therapeutic doses range from 5 to 10 mg, 
and the drug is metabolized in the liver and eliminated by 
the kidneys. In older people, and in cases of liver or kidney 
failure, the recommended dose is 5 mg73. Although the use 
of sleep inductors for treating chronic insomnia is only 
recommended for one month, clinic trials have suggested 
that zolpidem remains effective and safe for a prolonged 
period of use, i.e. more than 35 days, in a 10 mg doses74,75. 
The use of zolpidem reduces the cyclic alternating pat-
tern types A1 and A2, even when in intermittent use76,77.
Slow-release zolpidem (zolpidem MR, still not avail-
able in Brazil) is a new formulation used for patients with 
difficulty in maintaining their sleep. This formulation 
comprises pills with immediate release and pills for pro-
longed release, which maintains plasma concentrations for 
three to six hours after intake78,79. Zolpidem can also be 
used intermittently over the long term, in accordance with 
patient needs, without rebound insomnia appearing80-82.
[2] Zopiclone (recommended): This is a hypnotic drug 
that is recommended for treating insomnia. Zopiclone is 
a cyclopyrrolone that differs from zolpidem because of 
its longer half-life (5.3 hours) and its action on receptors 
containing the subunits α1 and α2. The recommended 
dose is 3.7 to 7.5 mg. A few side effects after withdrawal 
have been described; however, the residual effects on the 
following day may be attributed to its long half-life83.
[3] Zaleplon (recommended) - not available: This is 
a pyrazolopyrimidine that links to the α1 receptor, thus 
making the drug a hypnotic agent that can be recom-
mended for treating insomnia. The recommended dose is 
10 mg and its half-life is approximately one hour. Because 
of these characteristics, zaleplon is indicated for sleep in-
duction, while showing little effect on sleep maintenance. 
Zaleplon has already been in the Brazilian market, but it 
was withdrawn, which limits its use in this country 84.
[4] Eszopiclone (recommended) - not available: This 
is a zopiclone isomer of cyclopyrrolone that is recom-
mended for treating insomnia. Eszopiclone is rapidly ab-
sorbed and presents a relatively long half-life. The dose 
must be individualized, but ranges from 1 to 3 mg before 
going to bed85-87.
[5] Indiplon (recommended) - not available: This is a 
pyrazolopyrimidine with similarities to zolpidem, zopi-
clone and zaleplon that is selective for receptors that con-
tain a subunit α 1. It is a hypnotic drug recommended for 
treating insomnia. This drug has a formulation for imme-
diate release (indiplon IR), which is indicated for initial 
insomnia, and a controlled formulation (indiplon MR), 
which lasts six to eight hours and is indicated for patients 
with complaints regarding sleep maintenance. The rec-
ommended dose ranges from 15 to 30 mg, taken just be-
fore going to bed88.
Antidepressants
Sedative antidepressants (tricyclic, trazodone, doxe-
pin and mirtazapine) are alternatives for pharmacologi-
cal treatment of insomnia. However, there are no double-
blind randomized studies proving the efficacy and safe-
ty of these agents. Some tricyclic antidepressants such as 
amitriptyline improve sleep continuity and efficiency and 
produce sedation during the day89.
[1] Trazodone (recommended): Trazodone seems to be 
the second most commonly prescribed agent for treating 
insomnia. It belongs to the pharmacological group of se-
rotonin reuptake inhibitors, and has antagonist action on 
the adrenergic receptors α 1, 5-HT1A and 5-HT2. Tra-
zodone slightly suppresses REM sleep and improves sleep 
continuity. The recommended dose is 50 mg/day90.
[2] Doxepin (recommended): This is a tricyclic antide-
pressant with antagonist effect on histamine H1/H2 recep-
tors. It has been shown to be efficient if used in small doses 
(1 to 6 mg/night), for treating insomnia. It does not cause 
clinically significant residual or anti-cholinergic effects91.
[3] Mirtazapine (optional): This is an atypical anti-
depressant. Its mechanism of action depends on the in-
creased noradrenergic activity provided by the antago-
nist effect of the drug on alpha-2a adrenergic receptors, 
and nonspecific blockage of serotonergic reuptake. Mir-
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tazapine is a postsynaptic antagonist (blocker) of 5TH2A 
and 5TH 2C and 5-HT3 with sedative and anxiolytic ef-
fects. Its histaminic H1 anti-receptor activity explains the 
strong sedative effect, and this is the antidepressant with 
the greatest sedative effect among the currently available 
drugs. The recommended doses range from 7 to 30 mg92.
[4] Amitriptyline (optional): This presents significant 
sedative effects due to its anticholinergic, anti-histamin-
ic and anti-alpha1 profile, and also due to the blockage 
of 5HT2A and 5HT2C receptors. The sedative effects are 
immediate, preceding the antidepressant effects, and de-
crease after a few weeks of treatment. The recommend-
ed dose ranges from 12.5 to 50 mg.
[5] Mianserin (optional): This is an atypical antide-
pressant with sedative effect that occurs through anti-
histaminic 1 and 5HT2A/2C receptor antagonistic effects. 
There are no long-term studies proving the efficacy and 
safety of mianserin for treating insomnia. 
Valerian (optional)
Valerian (valepotriates) may be an option for treat-
ing insomnias and is used as an auxiliary medication 
when discontinuing benzodiazepine among chronic us-
ers. Some studies have reported that its mechanism of 
action is related to GABA. Valerian may act during sleep 
through other mechanisms, through MT1 and MT2 re-
ceptors (melatonin) and through the A1 adenosinergic re-
ceptor and some subtypes of 5-HT receptors93.
Benzodiazepines (optional)
Benzodiazepines (BZDs) link nonspecifically to the al-
pha-1 and alpha-2 subunits of the GABA-A postsynap-
tic receptor and to any subunit of the gamma type. BZDs 
increase the affinity of the GABA-A postsynaptic recep-
tor with endogenous GABA, and increase the intensi-
ty and duration of the inhibitory effects through boost-
ing chloride channels. The link to the subunit alpha-1 is 
responsible for the hypnotic and cognitive effects of this 
drug, while the link to the subunit alpha-2 is responsible 
for the anxiolytic, anti-convulsion and muscle-relaxing 
effects. Withdrawal of BZDs may bring back the insom-
nia or cause rebound insomnia in patients, with worse 
symptoms than those presented before treatment. The 
presence of anxiety and the intensity of insomnia depend 
on patients’ psychological profiles. Gradual and slow dis-
continuation of BZDs, with technical support, is recom-
mended. The abstinence symptoms when discontinuing 
BZDs depend on a variety of factors. Many chronic users 
will be able to discontinue treatment successfully, provid-
ed that it is done with an appropriate technique94-95.
Medication abuse often occurs among chronic users. 
Tolerance reflecting the progressive increase of BZD dos-
es also depends on several factors. However, there are pa-
tients who do not develop tolerance after using BZDs for 
a long time. There are studies demonstrating the existence 
of a correlation between prolonged use of BZDs and in-
creased risk of death. Amplification of obstructive ventila-
tory disorders during sleep, sedation, suppression of self-
care, falls, confusion, amnesia and other possible drug-
related symptoms may explain the increased mortality. 
BZDs are not indicated for individuals with drug addic-
tion and alcohol abuse. Special care is necessary with el-
derly individuals, patients with kidney, liver and lung dys-
functions, and patients with psychiatric problems. BZDs 
may worsen the ventilatory disorders during sleep and are 
not indicated during pregnancy, or for individuals whose 
work may require prompt waking up and quick decision-
making.
Among BZDs, clonazepam (optional), midazolam (op-
tional) and estazolam (optional) can be used. The other 
BZDs are not recommended.
Melatonin receptor agonists (optional)
[1] Ramelteon: This is a new hypnotic drug that has 
been approved for treating chronic insomnia. It is an ag-
onist with high selectivity for melatonin MT1 and MT2 
receptors96. The 8 mg recommended dose is rapidly ab-
sorbed (0.75-0.94 hour) and presents a half-life of 1.3 
hours. Due to its short half-life, Ramelteon is indicated 
for treating initial insomnia97-99. It is not efficient in main-
taining sleep. Ramelteon is safe with regard to cognitive 
effects on the following day, and has not been shown to 
cause rebound insomnia when discontinued after chron-
ic use. It has not shown any potential for abusive use or 
dependence100-102.
[2] Agomelatine: This is an antidepressant with agonist 
action on melatonin receptors 1 and 2, and antagonist ef-
fect on serotoninergic 5-HT2C receptors. Because of its 
melatoninergic agonist effect, agomelatine may be a po-
tential regulator of the circadian rhythm of depressed pa-
tients, thus leading to an added contribution for improv-
ing depression. Use of this medication at a dose of 25 to 
50 mg has been shown to improve sleep quality, with re-
duced sleep latency, reduced awakening and increased 
slow-wave sleep103,104.
Other pharmacological and new perspectives
Antihistamines are optional, while antipsychotics are 
not recommended.
New GABA agonists, like tiagabine and gaboxadol, 
are still not available in Brazil and are not recommend-
ed. These drugs are inhibitors of GABA reuptake, and are 
among the new perspectives for treating insomnia105-110.
Insomnia during childhood
Classification (standard)
Insomnia during childhood is divided into behavior-
al insomnia, psychophysiological insomnia, insomnia 
in special populations, insomnia associated with clini-
cal conditions and insomnia associated with the use of 
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medications. The most common clinical causes of insom-
nia during childhood are pain or cramps, recurrent oti-
tis, reflux, medications (stimulants or corticoids), night 
asthma attacks and airway obstructions.111 The main type 
of insomnia in children is behavioral insomnia, but this 
is an exclusion diagnosis. During the first approach to-
wards the child, the clinical causes of insomnia must al-
ways be eliminated.
[1] Behavioral insomnia during childhood: This oc-
curs in 10 to 30% of preschool children. The Internation-
al Classification of Sleep Disorders (ICSD-2005) defines 
children’s difficulty in falling asleep and/or maintaining 
sleep as the essential characteristic of behavioral insom-
nia. These problems are associated with certain attitudes 
among children or their parents, and they can be classi-
fied into two types: association disorder and lack-of-lim-
it disorder112.
[2] Association disorder: There are certain conditions 
associated with the start of sleep that are necessary for 
children to fall asleep and for them to go back to bed af-
ter each awakening during the night. Positive associations 
are conditions that children can provide for themselves 
(pacifiers/dummies or teddy bears), while negative associ-
ations need assistance from someone else (baby bottles or 
rocking). The negative associations also include external 
stimuli (television or toys) or different situations (parents’ 
bed or a car ride). When the condition associated with 
sleep is present, the child falls asleep rapidly. If the con-
dition associated with sleep is not present, the child pres-
ents frequent and long-duration nighttime awakenings.
The diagnostic criteria consist of findings that falling 
asleep is a slow process that requires special conditions, 
and that associations with falling asleep are problematic 
and require much effort. When association elements are 
absent, the start of sleep is significantly delayed or sleep is 
fragmented. Nighttime awakening requires intervention 
so that these children can fall asleep again.
[3] Lack-of-limit disorder: This is presented as a refus-
al or delay in going to bed at the established time. On the 
other hand, delaying the time for going to sleep might in-
clude several requests (feeling thirsty, needing the bath-
room or asking for one more goodnight kiss) or addi-
tional activities (watching TV or reading one more sto-
ry). Once these children fall asleep, their sleep quality is 
normal and they tend to have few awakenings. Howev-
er, children with lack-of-limit disorder normally have a 
shorter sleeping time (30 to 60 minutes). 
The diagnostic criteria consist of difficulty in falling 
asleep or maintaining sleep; postponing or refusing to go 
to bed at the appropriate time or refusing to go back to 
bed after nighttime awakening; inability of the parents to 
establish appropriate sleep behavior for the child; lack of 
explanation for the sleep disorder in terms of other sleep 
disorders, clinical conditions, mental or neurological dis-
eases, or use of medications.
[4] Insomnia associated with neurological and psychi-
atric conditions: Most syndromes with central nervous 
system dysfunction present some kind of sleep abnor-
mality in their clinical presentation.
Diagnosis
Medical evaluation (standard) - The main questions 
in evaluating sleep disorders in pediatric cases include 
duration of sleep, sleep routines, events associated with 
sleep, daily behavior, humor and cognitive function. It is 
also essential to find out about significant events in the 
child’s life, such as parents’ divorce, changes of school or 
moving house, or events involving siblings. A sleep diary 
must be kept over a one or two-week period, and this is 
always useful for finding out about sleeping patterns and 
for following them over time. Parents are asked to write 
details about what time the child went to bed, how long 
the child took to fall asleep, the frequency and duration 
of nighttime awakening, the time and duration of daily 
naps, the time of waking up in the morning and the total 
duration of sleep113.
Polysomnography (optional): Polysomnographic testing 
and actigraphy are optional in diagnosing and treating in-
somnia in children. They are indicated only when necessary.
Consequences
Children with insufficient duration of sleep present fa-
tigue and irritability. Parents may present negative feel-
ings towards their children and, in order to avoid frustra-
tions during sleeping times, they may postpone the sleep 
routine, which delays the start of sleep even more and 
prolongs the cycle of addiction.
Treatment 
[1] Behavioral approach (standard): Time for going 
to sleep: The appropriate time for a child to go to sleep, 
from infancy to preschool age, should be between 7:00 
and 8:30 pm. When bedtime is later than this, children 
get very tired, irritated and have difficulty in sleeping. The 
time for going to sleep should not vary between weekdays 
and weekends. Daytime naps are essential for the child. 
The need for daytime naps tends to disappear between 
the ages of three and six years114.
Bedtime routine: Establishing a routine is very impor-
tant for children’s lives. The bedtime routine can be start-
ed at three months of age, through establishing a con-
stant time for going to sleep. Any electronic equipment 
near the child must be turned off before starting the rit-
ual for going to sleep.
Falling asleep independently: Children with insomnia 
are incapable of falling asleep without their parents’ in-
tervention, such as rocking or feeding. Children must be 
put in the cradle or go to bed when they are sleepy, but 
still awake, and then they must fall asleep independently. 
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There are several methods that help children fall asleep by 
themselves, for example, “extinction” alone, gradual “ex-
tinction”, positive routines, brief visits and weaning chil-
dren from their parents’ presence115.
“Extinction” alone consists of leaving the child cry un-
til falling sleep. “Extinction” is based in the theory that be-
havior that is reinforced increases in frequency, while be-
havior that is ignored will disappear with time. If parents 
are regular and do not attend their child’s calls, in gener-
al, the child will be able to sleep alone after three to five 
nights. Gradual extinction is an alternative for parents 
who do not want to use extinction alone. This method 
consists of putting the sleepy, but awake, child in the cra-
dle and then ignoring the calls or crying for gradually in-
creasing periods. When observing the child at night, the 
visit must be short and uniform, without lights and with-
out speaking loudly or touching the child. 
The gradual reduction of the mother’s presence in-
cludes an initial phase in which physical contact is re-
duced at bedtime. Mothers who feed their children at 
bedtime must do this activity earlier in another room and 
only rock the child to sleep. After achieved success with 
this strategy, the child must be put in the cradle and the 
mother must caress the child’s head or arm until the child 
falls asleep. In the second step, the mother’s presence in 
the bedroom must be reduced. The third step consists of 
increasing the time between each visit. Positive routines 
aim to create a pleasant and positive environment not 
only for the child but also for the parents. 
[2] Pharmacological treatment (optional): Pharmaco-
logical treatment must be considered as the last option. 
Most medications prescribed for insomnia among adults 
are not recommended for children. However, in specific 
cases, generally when there is an underlying neurologi-
cal or psychiatric disease, BDZs can be used (clonazepam, 
clobazam, midazolam or diazepam), as well as zolpidem, 
zopiclone, chloral hydrate, levomepromazine, promethaz-
ine, carbamazepine, clonidine, risperidone and melatonin, 
always considering the age of the child and the risk/ben-
efit associated with the use of these drugs116.
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